Thursday, 5 November 2026European Markets

ARKEMA And 4 Other Stocks Have Very High Payout Ratio

Loading stream...

(vianews) - maroc telecom (iam.pa), arkema (ake.pa), axa (cs.pa) are the highest payout ratio stocks on this list.

here's the data we've collected of stocks with a high payout ratio up to now. the payout ratio in itself isn't a promise of a future good investment but it's an indicator of whether dividends are being paid and how the company chooses to distribute them.

when investigating a potential investment, the dividend payout ratio is a good statistic to know so here is a list of some companies with an above 30% payout ratio.

1. maroc telecom (iam.pa)

153.15% payout ratio

earnings per share

as for profitability, maroc telecom has a trailing twelve months eps of €0.53.

pe ratio

maroc telecom has a trailing twelve months price to earnings ratio of 17.17. meaning, the purchaser of the share is investing €17.17 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.58%.

more news about maroc telecom.

2. arkema (ake.pa)

72.96% payout ratio

earnings per share

as for profitability, arkema has a trailing twelve months eps of €4.56.

pe ratio

arkema has a trailing twelve months price to earnings ratio of 18.42. meaning, the purchaser of the share is investing €18.42 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4.85%.

moving average

arkema's value is below its 50-day moving average of €86.94 and way under its 200-day moving average of €93.61.

revenue growth

year-on-year quarterly revenue growth declined by 7.3%, now sitting on 9.33b for the twelve trailing months.

yearly top and bottom value

arkema's stock is valued at €84.00 at 11:10 est, way below its 52-week high of €104.40 and above its 52-week low of €79.85.

more news about arkema.

3. axa (cs.pa)

59.03% payout ratio

earnings per share

as for profitability, axa has a trailing twelve months eps of €3.23.

pe ratio

axa has a trailing twelve months price to earnings ratio of 10.91. meaning, the purchaser of the share is investing €10.91 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.77%.

volume

today's last reported volume for axa is 1125160 which is 65.77% below its average volume of 3287910.

more news about axa.

4. frontline (fro.ol)

40.94% payout ratio

earnings per share

as for profitability, frontline has a trailing twelve months eps of kr29.18.

pe ratio

frontline has a trailing twelve months price to earnings ratio of 8.11. meaning, the purchaser of the share is investing kr8.11 for every norwegian krone of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 33.1%.

revenue growth

year-on-year quarterly revenue growth grew by 128.7%, now sitting on 1.71b for the twelve trailing months.

earnings before interest, taxes, depreciation, and amortization

frontline's ebitda is 192.84.

dividend yield

as stated by morningstar, inc., the next dividend payment is on jun 15, 2023, the estimated forward annual dividend rate is 20.26 and the estimated forward annual dividend yield is 10.59%.

more news about frontline.

5. elopak (elo.ol)

32.57% payout ratio

earnings per share

as for profitability, elopak has a trailing twelve months eps of kr3.09.

pe ratio

elopak has a trailing twelve months price to earnings ratio of 14.85. meaning, the purchaser of the share is investing kr14.85 for every norwegian krone of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 22.46%.

yearly top and bottom value

elopak's stock is valued at kr45.90 at 11:10 est, way above its 52-week high of kr26.00.

dividend yield

as stated by morningstar, inc., the next dividend payment is on may 12, 2023, the estimated forward annual dividend rate is 0.86 and the estimated forward annual dividend yield is 3.83%.

moving average

elopak's value is way above its 50-day moving average of kr22.63 and way above its 200-day moving average of kr23.47.

more news about elopak.

1. 1 (1)

1% payout ratio

1

earnings per share

as for profitability, 1 has a trailing twelve months eps of €1.

pe ratio

1 has a trailing twelve months price to earnings ratio of 1. meaning, the purchaser of the share is investing €1 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 1%.

revenue growth

year-on-year quarterly revenue growth grew by 1%, now sitting on 1 for the twelve trailing months.

growth estimates quarters

the company's growth estimates for the current quarter and the next is 1% and 1%, respectively.

sales growth

1's sales growth is 1% for the current quarter and 1% for the next.

earnings before interest, taxes, depreciation, and amortization

1's ebitda is 1.

more news about 1.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com